Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by MaaT Pharma

< Previous 1 2 3 Next >
MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting
From MaaT Pharma
Via Business Wire
MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting
From MaaT Pharma
Via Business Wire
MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference
From MaaT Pharma
Via Business Wire
MaaT Pharma Reports Cash and Revenues for Third Quarter 2022
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Participation in Scientific and Investor Conferences in November
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Oral and Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
From MaaT Pharma
Via Business Wire
MaaT Pharma Appoints Nathalie Corvaïa as Chief Scientific Officer and Strengthens its R&D Activities in Immuno-Oncology
From MaaT Pharma
Via Business Wire
MaaT Pharma Publishes its Half Year Results and Provides a Business Overview
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Participation in Three Upcoming Investor Conferences in September
From MaaT Pharma
Via Business Wire
MaaT Pharma Reports Cash and Revenues for Second Quarter 2022
From MaaT Pharma
Via Business Wire
MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients
From MaaT Pharma
Via Business Wire
MaaT Pharma to Host First Virtual R&D Day on June 7th, 2022
From MaaT Pharma
Via Business Wire
MaaT Pharma Reports Cash and Revenues for First Quarter 2022
From MaaT Pharma
Via Business Wire
INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial
From MaaT Pharma
Via Business Wire
MaaT Pharma Publishes its 2021 Annual Results and Provides a Business Overview
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces the Initiation of a Phase 2a Investigator-Sponsored Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors for Patients with Melanoma
From MaaT Pharma
Via Business Wire
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces the Implementation of a Liquidity Contract with Kepler Cheuvreux
From MaaT Pharma
Via Business Wire
MaaT Pharma to Present Promising Clinical Data for Lead Therapeutic Candidate MaaT013 at 48th EBMT Annual Meeting
From MaaT Pharma
Via Business Wire
MaaT Pharma Reports Cash and Revenues for Full-Year 2021
From MaaT Pharma
Via Business Wire
MaaT Pharma and Skyepharma Have Entered a Partnership to Establish the First Exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study
From MaaT Pharma
Via Business Wire
MaaT Pharma Provides Business Objectives and Expected Milestones for 2022
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas
From MaaT Pharma
Via Business Wire
MaaT Pharma to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
From MaaT Pharma
Via Business Wire
MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting
From MaaT Pharma
Via Business Wire
MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013
From MaaT Pharma
Via Business Wire
MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
From MaaT Pharma
Via Business Wire
MaaT Pharma Awarded France Relance Government Grant to Accelerate Development in Immuno-Oncology and Support Manufacturing of Next Generation Microbiome Therapies
From MaaT Pharma
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.